AbbVie (ABBV) Raises Quarterly Dividend 12.3% to $0.64; 4.2% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Credit Suisse Downgrades Abbvie (ABBV) to Neutral; Path to Upside Difficult
October 31, 2016 7:13 AM EDTCredit Suisse downgraded Abbvie (NYSE: ABBV) from Outperform to Neutral with a price target of $60.00 (from $70.00), saying while valuation may be compelling the path to upside is difficult.
Analyst Vamil Divan commented, "We downgrade ABBV shares to Neutral and lower our target price to $60 (from... More
AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook
October 28, 2016 7:44 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $1.21, $0.01 better than the analyst estimate of $1.20. Revenue for the quarter came in at $6.43 billion versus the consensus estimate of $6.56 billion.
Global HUMIRA sales increased 11.3 percent on a reported basis. Operational HUMIRA sales increased 12.1 percent, excluding a... More